Calyx Delivers Imaging Biomarkers to Advance Neuropsychiatric Treatment Development

Calyx, the eClinical and Regulatory solutions and services provider relied on for solving complex data challenges in clinical research, announced a strategic partnership with Ceretype Neuromedicine, Inc., whose novel functional MRI (fMRI) platform incorporates optimal image acquisition and advanced analytics to de-risk and accelerate the development of psychiatric and neurological therapies.

Recommended AI: GoodFirms Unlocks the Best Task Management Software with Rich Features

The current lack of objective biomarkers presents a real challenge for researchers developing treatments for depression/anxiety, schizophrenia, and other neurological/psychiatric conditions such as Parkinson’s Disease. An in-market, audit-cleared “biomarker engine,” the Ceretype platform utilizes cutting-edge fMRI and artificial intelligence (AI) to connect neural circuitry to patient behaviors and treatment outcomes, delivering the objective biologic endpoints researchers need for more precise measurement of treatment effects during central nervous system (CNS) drug development.

“A key component of Calyx’s strategy is partnering with best-in-class technology providers to offer the innovative imaging biomarkers required to find new treatments for unmet medical needs,” said Stephen M. Bravo, MD, Chief Medical Officer at Calyx. “We’re excited to partner with Ceretype and for our customers to leverage their advanced fMRI technology to bring new and more effective psychiatric treatments to market.”

Recommended AI: aelf Announces the form of aelf DAO, Enhancing Decentralization of Governance and Ecosystem Growth

“We’re delighted to combine Ceretype’s neuroscience, biophysics, and computing expertise with Calyx’s 25 years of experience delivering reliable clinical trial imaging,” said Emily Stern, CEO at Ceretype. “Through this partnership, we will achieve our mission of improving psychiatric and neurologic patient outcomes through precision drug development and precision treatment.”

Recommended AI: Adelante Enhances Capabilities with Zendesk Setup Solution

[To share your insights with us, please write to sghosh@martechseries.com]

The post Calyx Delivers Imaging Biomarkers to Advance Neuropsychiatric Treatment Development appeared first on AiThority.

biomarkers
medical
artificial intelligence
ai
software